AU2013269606B2 - P2X7 receptor antagonists and agonists - Google Patents

P2X7 receptor antagonists and agonists Download PDF

Info

Publication number
AU2013269606B2
AU2013269606B2 AU2013269606A AU2013269606A AU2013269606B2 AU 2013269606 B2 AU2013269606 B2 AU 2013269606B2 AU 2013269606 A AU2013269606 A AU 2013269606A AU 2013269606 A AU2013269606 A AU 2013269606A AU 2013269606 B2 AU2013269606 B2 AU 2013269606B2
Authority
AU
Australia
Prior art keywords
gly
ser
val
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013269606A
Other languages
English (en)
Other versions
AU2013269606A1 (en
Inventor
Toon Laeremans
Friedrich Nolte
Welbeck Owusu Danquah
Catelijne Stortelers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ablynx NV
University Medical Center Hamburg-Eppendorf
Original Assignee
Ablynx NV
University Medical Center Hamburg-Eppendorf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx NV, University Medical Center Hamburg-Eppendorf filed Critical Ablynx NV
Publication of AU2013269606A1 publication Critical patent/AU2013269606A1/en
Assigned to UNIVERSITY MEDICAL CENTER HAMBURG - EPPENDORF, ABLYNX N.V. reassignment UNIVERSITY MEDICAL CENTER HAMBURG - EPPENDORF Amend patent request/document other than specification (104) Assignors: ABLYNX N.V.
Application granted granted Critical
Publication of AU2013269606B2 publication Critical patent/AU2013269606B2/en
Priority to AU2018217239A priority Critical patent/AU2018217239B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2013269606A 2012-06-01 2013-05-31 P2X7 receptor antagonists and agonists Active AU2013269606B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018217239A AU2018217239B2 (en) 2012-06-01 2018-08-14 P2X7 receptor antagonists and agonists

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654417P 2012-06-01 2012-06-01
US61/654,417 2012-06-01
PCT/EP2013/061257 WO2013178783A1 (en) 2012-06-01 2013-05-31 P2x7 receptor antagonists and agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018217239A Division AU2018217239B2 (en) 2012-06-01 2018-08-14 P2X7 receptor antagonists and agonists

Publications (2)

Publication Number Publication Date
AU2013269606A1 AU2013269606A1 (en) 2014-12-18
AU2013269606B2 true AU2013269606B2 (en) 2018-05-17

Family

ID=48579032

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013269606A Active AU2013269606B2 (en) 2012-06-01 2013-05-31 P2X7 receptor antagonists and agonists
AU2018217239A Active AU2018217239B2 (en) 2012-06-01 2018-08-14 P2X7 receptor antagonists and agonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018217239A Active AU2018217239B2 (en) 2012-06-01 2018-08-14 P2X7 receptor antagonists and agonists

Country Status (6)

Country Link
US (2) US9908935B2 (enExample)
EP (1) EP2855518A1 (enExample)
JP (2) JP6608698B2 (enExample)
CN (1) CN104507964B (enExample)
AU (2) AU2013269606B2 (enExample)
WO (1) WO2013178783A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2747644C (en) 2008-12-19 2023-01-24 Ablynx N.V. Method for generation of immunoglobulin sequences
JP6608698B2 (ja) 2012-06-01 2019-11-27 アブリンクス エン．ヴェー． Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト
WO2014182601A1 (en) * 2013-05-08 2014-11-13 Children's Medical Center Corporation A method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the atp/p2x7r axis)
LT3248986T (lt) 2014-05-16 2022-03-25 Ablynx Nv Imunoglobulino kintami domenai
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
CN107614528A (zh) * 2015-04-02 2018-01-19 生物权威（英国）有限公司 疼痛治疗
JP7403224B2 (ja) * 2015-11-12 2023-12-22 アブリンクス エン．ヴェー． 改良されたｐ２ｘ７受容体結合剤およびこれを含むポリペプチド
PL233352B1 (pl) * 2016-09-15 2019-10-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe białko fuzyjne
CN109321589A (zh) * 2018-10-15 2019-02-12 潍坊医学院 一种制备p2x7r免疫原的方法
CN110054691B (zh) * 2019-05-09 2021-09-07 潍坊医学院 一种抗人p2rx7单克隆抗体的杂交瘤细胞系
CA3152181A1 (en) * 2019-08-23 2021-03-04 Unm Rainforest Innovations Non-opioid compositions and therapies for pain management
WO2022114122A1 (ja) 2020-11-30 2022-06-02 旭化成ファーマ株式会社 神経障害性疼痛を緩和させるための医薬
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
IL322519A (en) 2023-02-17 2025-10-01 Ablynx Nv Polypeptides that bind to the neonatal fc receptor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010070145A2 (en) * 2008-12-19 2010-06-24 Ablynx N.V. Method for generation of immunoglobulin sequences

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344860B2 (en) * 2003-04-03 2008-03-18 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
US8124730B1 (en) * 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
JP6608698B2 (ja) 2012-06-01 2019-11-27 アブリンクス エン．ヴェー． Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010070145A2 (en) * 2008-12-19 2010-06-24 Ablynx N.V. Method for generation of immunoglobulin sequences

Also Published As

Publication number Publication date
CA2875234A1 (en) 2013-12-05
AU2018217239A1 (en) 2018-08-30
JP2018162269A (ja) 2018-10-18
EP2855518A1 (en) 2015-04-08
CN104507964A (zh) 2015-04-08
AU2013269606A1 (en) 2014-12-18
JP6681433B2 (ja) 2020-04-15
JP6608698B2 (ja) 2019-11-27
AU2018217239B2 (en) 2020-07-30
US10544216B2 (en) 2020-01-28
JP2015525211A (ja) 2015-09-03
US9908935B2 (en) 2018-03-06
US20180244769A1 (en) 2018-08-30
WO2013178783A1 (en) 2013-12-05
US20150133637A1 (en) 2015-05-14
CN104507964B (zh) 2020-05-15

Similar Documents

Publication Publication Date Title
US10544216B2 (en) P2X7 receptor antagonists and agonists
US12221487B2 (en) Nucleic acids encoding CX3CR1-binding polypeptides comprising immunoglobulin single variable domains
JP2013519364A (ja) アゴニストｄｒ５結合ポリペプチド
CA2834907A1 (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
AU2016352695B2 (en) Improved P2X7 receptor binders and polypeptides comprising the same
CA2875234C (en) P2x7 receptor antagonists and agonists
HK40077734A (en) Cx3cr1-binding polypeptides
HK1205154B (en) Cx3cr1-binding polypeptides

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)